| scholarly article | Q13442814 |
| P50 | author | Luisa Carbognin | Q40709086 |
| Maria Vittoria Dieci | Q57656975 | ||
| P2093 | author name string | Federica Miglietta | |
| Ida Paris | |||
| P2860 | cites work | TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta | Q24310394 |
| Nuclear PTEN regulates the APC-CDH1 tumor-suppressive complex in a phosphatase-independent manner | Q24337323 | ||
| MiR-222 promotes drug-resistance of breast cancer cells to adriamycin via modulation of PTEN/Akt/FOXO1 pathway | Q38740895 | ||
| De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance | Q39421814 | ||
| Relationship between tumor biomarkers and efficacy in TH3RESA, a phase III study of trastuzumab emtansine (T-DM1) vs. treatment of physician's choice in previously treated HER2-positive advanced breast cancer | Q39591068 | ||
| PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. | Q39767744 | ||
| Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer | Q41037554 | ||
| Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies. | Q41149668 | ||
| PTEN expression is upregulated by a RNA-binding protein RBM38 via enhancing its mRNA stability in breast cancer | Q42668728 | ||
| PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer | Q43700699 | ||
| Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. | Q45945230 | ||
| Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy | Q46796554 | ||
| Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial | Q47963228 | ||
| Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer | Q48354684 | ||
| PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. | Q27824819 | ||
| A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer | Q27851414 | ||
| The Selective Class I PI3K Inhibitor CH5132799 Targets Human Cancers Harboring Oncogenic PIK3CA Mutations | Q27851644 | ||
| Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor | Q27853093 | ||
| Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3. | Q27853377 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms | Q28181035 | ||
| Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers | Q28306997 | ||
| The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| The functions and regulation of the PTEN tumour suppressor | Q29615536 | ||
| Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells | Q33564297 | ||
| PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib | Q33933626 | ||
| Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapa | Q34296114 | ||
| Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study | Q34485373 | ||
| Loss of Phosphatase and Tensin Homolog or Phosphoinositol-3 Kinase Activation and Response to Trastuzumab or Lapatinib in Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancers | Q34679149 | ||
| Subtle variations in Pten dose determine cancer susceptibility | Q35055350 | ||
| Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. | Q35058975 | ||
| PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance | Q35562967 | ||
| Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors | Q36042091 | ||
| Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer | Q36064908 | ||
| Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial | Q37065849 | ||
| An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer | Q37187915 | ||
| Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status | Q37221249 | ||
| Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. | Q37350792 | ||
| Pten in stromal fibroblasts suppresses mammary epithelial tumours | Q37399478 | ||
| Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways | Q37425090 | ||
| Indirect mechanisms of carcinogenesis via downregulation of PTEN function. | Q37628849 | ||
| Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer | Q37633741 | ||
| PD-L1 expression in triple-negative breast cancer | Q37724790 | ||
| Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy | Q37783931 | ||
| Emerging role of microRNAs in drug-resistant breast cancer. | Q37977960 | ||
| Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer | Q52857952 | ||
| Successful targeting of ErbB2 receptors-is PTEN the key? | Q54292650 | ||
| Translational studies within the TAMRAD randomized GINECO trial: evidence for mTORC1 activation marker as a predictive factor for everolimus efficacy in advanced breast cancer | Q54312158 | ||
| Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer. | Q55371418 | ||
| Molecular profiling of hormone receptor-positive, HER2-negative breast cancers from patients treated with neoadjuvant endocrine therapy in the CARMINA 02 trial (UCBG-0609) | Q57280932 | ||
| Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor-Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial | Q60682617 | ||
| Breast cancer--loss of PTEN predicts resistance to treatment | Q81059127 | ||
| PTEN-opathies: from biological insights to evidence-based precision medicine | Q90918120 | ||
| Inhibition of Nuclear PTEN Tyrosine Phosphorylation Enhances Glioma Radiation Sensitivity through Attenuated DNA Repair | Q91992666 | ||
| Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer | Q92413714 | ||
| FAIRLANE, a double-blind placebo-controlled randomized phase II trial of neoadjuvant ipatasertib plus paclitaxel for early triple-negative breast cancer | Q92420033 | ||
| PTEN as a Prognostic/Predictive Biomarker in Cancer: An Unfulfilled Promise? | Q92702101 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 9 | |
| P577 | publication date | 2019-09-19 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Cancers | Q27722963 |
| P1476 | title | Prognostic and Predictive Implications of PTEN in Breast Cancer: Unfulfilled Promises but Intriguing Perspectives | |
| P478 | volume | 11 |
| Q89878532 | PTEN Expression as a Complementary Biomarker for Mismatch Repair Testing in Breast Cancer |
| Q100513595 | SRY-related high-mobility-group box 6 suppresses cell proliferation and is downregulated in breast cancer |
Search more.